Leaving the study early · adults with panic disorder
Selective serotonin reuptake inhibitors showed no clear difference in total number of dropouts compared with placebo (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · adults with panic disorder
Selective serotonin reuptake inhibitors probably leads to lower failure to remit compared with placebo (moderate certainty).
1 finding from 1 review
panic symptoms · adults with panic disorder
2 findings from 1 review
Withdrawals due to adverse events · adults with panic disorder
Selective serotonin reuptake inhibitors probably leads to higher number of dropouts due to adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Subjective sleep quality or quantity · adults with insomnia
1 finding from 1 review
Other subjective measures of sleep (total sleep time, sleep onset latency, nocturnal awakenings and subjective sleep efficiency) (PSQI) (at 12 weeks) · adults with insomnia
1 finding from 1 review
Adverse events (at 12 weeks) · adults with insomnia
1 finding from 1 review
PSG sleep outcomes (at 12 weeks) · adults with insomnia
1 finding from 1 review
Overall mortality · people with systemic sclerosis
Autologous non‐myeloablative selective HSCT showed no clear difference in overall mortality compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Event‐free survival · people with systemic sclerosis
Autologous non‐myeloablative selective HSCT probably leads to lower event‐free survival compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Functional ability · people with systemic sclerosis
1 finding from 1 review
Skin thickness – mRSS Scale 0–51 in which a higher number is worse skin thickening · people with systemic sclerosis
1 finding from 1 review
Interstitial lung disease – FVC % predicted A lower percentage represents worse lung disease · people with systemic sclerosis
1 finding from 1 review
Pulmonary arterial hypertension · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with systemic sclerosis
Autologous non‐myeloablative selective HSCT probably leads to higher serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression
Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with atypical agent (low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression
Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with atypical agent (low certainty).
1 finding from 1 review
Dropout · adults living with HIV and depression
Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in study dropouts at 6‐12 weeks compared with atypical agent (low certainty).
1 finding from 1 review
Dropout · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes study dropouts at 6‐12 weeks compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review